Program Manager - People & Culture PMO
About the job
- A bachelor's degree in Business, Project Management, Human Resources, Technology, or a related field is required.
- At least 8 years of progressive experience in Project Management, Program Management, PMO Leadership, or Portfolio Management is required.
- At least 5 years leading enterprise or large-scale portfolios with multiple concurrent projects is required.
- Experience managing strategic project portfolios is required.
- Demonstrated experience implementing PMO governance frameworks and operating models is required.
- Experience tracking resource allocation, workforce capacity, and project demand planning is required.
- Experience developing business cases, measuring return on investment, and tracking benefits realization is required.
- Strong executive communication and stakeholder management skills are required.
- Experience working in global, matrixed organizations is required.
- Establish and mature the People & Culture PMO operating model, governance framework, and portfolio management processes.
- Develop a consistent project intake, prioritization, approval, and monitoring process for HR initiatives.
- Lead regular governance reviews of strategic projects, ensuring executive visibility into status, risks, dependencies, and key decisions.
- Facilitate monthly and quarterly portfolio reviews with People & Culture leadership.
- Ensure projects align with organizational priorities, strategic goals, and available capacity.
- Partner with Enterprise PMO leaders to adopt and maintain enterprise project management standards, templates, methodologies, and reporting requirements.
- Manage the People & Culture project portfolio, including HR Technology, Talent, Total Rewards, Employee Experience, Workforce Management, AI, Compliance, and operational excellence initiatives.
- Maintain portfolio-level visibility into investment decisions, timelines, interdependencies, and business outcomes.
- Support executive decision-making through portfolio analytics and reporting.
- Establish project prioritization frameworks to ensure resources focus on initiatives delivering the highest business value.
- Develop and maintain resource planning processes across People & Culture functions.
- Track demand versus capacity across project teams and improvement initiatives.
- Identify resource constraints, conflicts, and allocation risks.
- Partner with leaders to optimize utilization, sequencing, and timing of work.
- Provide leadership with workforce and project capacity insights to support planning decisions.
- Oversee project status reporting standards across all People & Culture initiatives.
- Lead portfolio-level risk, issue, assumption, and dependency management.
- Drive consistent use of project management disciplines across projects.
- Ensure projects maintain clear scope, milestones, success metrics, and accountability.
- Partner with project teams to proactively resolve delivery challenges.
- Establish business case development standards for strategic initiatives.
- Define and track project success measures, key performance indicators, benefits realization, and return on investment.
- Provide executive reporting on expected and realized value from investments.
- Ensure projects have measurable outcomes aligned to business objectives.
- Serve as the People & Culture project management subject matter expert.
- Coach and mentor HR practitioners acting in project manager roles, HR leaders, and project sponsors on project management best practices.
- Improve organizational project management maturity through training, templates, tools, and governance.
- Develop communities of practice and project management standards across People & Culture.
- Partner with the Process Excellence team to track and govern operational improvement initiatives.
- Monitor improvement pipelines, benefit realization, and execution progress.
- Promote continuous improvement methodologies and disciplined execution practices.
- Leverage generative artificial intelligence tools to support program management tasks and governance.
- PMP (Project Management Professional) certification.
- PgMP (Program Management Professional) certification.
- PfMP (Portfolio Management Professional) certification.
- PMI-PMOCP (PMO Certified Professional) certification.
- PRINCE2 Practitioner certification.
- PMI-ACP (Agile Certified Practitioner) certification.
- Lean Six Sigma Green Belt or Black Belt certification.
- Experience supporting Human Resources, People & Culture, HR Technology, or Transformation organizations.
- Experience with Workday and HR technology deployments.
- Experience supporting enterprise governance councils and executive steering committees.
- Familiarity with Planview, Clarity, Microsoft Project, Smartsheet, or similar portfolio management tools.
- Experience partnering with Process Excellence or Continuous Improvement teams.
About the company
iRhythm Technologies develops cardiac monitoring technology centered on the Zio Patch, a wearable device that records heart rhythms for up to 14 days. The patch is worn by patients to collect continuous heart data, which iRhythm analyzes and interprets to provide diagnostic insights to clinicians without frequent in-person visits. Compared with rivals, the Zio Patch focuses on long-duration, non-intrusive monitoring combined with integrated data analysis that supports telehealth and clinician workflows. Its goal is to improve arrhythmia detection and diagnostic accuracy while streamlining patient care through scalable wearable monitoring and data interpretation.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2006
Get referred to iRhythm Technologies
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $224.2 million, up 20.1%, with 19.3% EBITDA margin.
- Management raised 2026 revenue guidance to $880 million-$890 million on August 6, 2026.
- VitalConnect's $65 million run-rate expands iRhythm into MCT and inpatient channels.
What critics are saying
- June 8, 2026 breach exposed PHI; class actions filed in Northern California.
- FDA warning letter on Zio AT remains open, delaying full regulatory normalization.
- Baxter settlement cost $50 million; VitalConnect integration risk starts before 2027 synergies.
What makes iRhythm Technologies unique
- Zio integrates wearables, AI review, and cloud workflows across ambulatory cardiac monitoring.
- August 6, 2026 VitalConnect adds 30-day MCT and hospital-to-home monitoring.
- iRhythm serves 8 million patients, giving unmatched installed trust and clinical data scale.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Mental Health Support
Hybrid Work Options
Pet Insurance
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%After ransomware attack, medical device maker alerting victims. Oct 9, 2026 | News By Gregory Hale San Francisco, California-based medical device maker, iRhythm Holdings, Inc., suffered a ransomware attack in June and is now informing victims of the attack. "On June 8, 2026, iRhythm Holdings, Inc. identified unauthorized activity involving data maintained on certain third-party-hosted business applications," the company said in a June filing with the Securities and Exchange Commission (SEC). "The company promptly activated its cybersecurity response plan and launched an investigation with the support of external advisors and cybersecurity experts to assess and contain the threat. "On June 9, 2026, the company received communications from a threat actor claiming to have obtained sensitive information, including proprietary data, patient protected health information and other personal information. The communications from the threat actor demanded payment in exchange for not publicly disclosing this information. "Since receipt of the communications, the company has confirmed that certain data was exfiltrated from those applications. On June 10, 2026, the company determined that the incident is material in light of the volume of the potentially affected data," the SEC notice said. The company said 298,647 people in Texas had information stolen alongside another 69,526 in South Carolina. iRhythm also filed breach notices in California. Attackers gained access. After the company completed its forensic investigation, it found attackers were on the site from June 3 through June 8. The hackers gained access to unidentified third-party-hosted business applications through a social engineering attack. On October 2 iRhythm provided an update regarding the incident. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company just started notifying impacted individuals. Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: Patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth. iRhythm said it has no evidence any personal information has been or will end up used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information. The company said out of an abundance of caution, those served by iRhythm should take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis. No impact to manufacturing. As iRhythm previously reported to the SEC, the company has not identified any impact to its products, clinical or medical device systems, connections to customers, manufacturing and distribution operations, patient safety, or ability to meet patient needs. The company still believes the incident will not have a material impact on its financial condition or results of operations. It said cybersecurity insurance that may cover certain losses associated with the incident. Although, it added, there can be no assurance that such coverage will be sufficient to cover all losses the company may incur. iRhythm manufactures its line of prescription-only ECG patch monitors and cardiac systems. iRhythm designs, develops, and commercializes wearable biosensors (such as the Zio monitor, Zio XT, and Zio AT) alongside cloud-based data analytics and its proprietary AI-driven Zio ECG Utilization Software (ZEUS). No further information was immediately available on who was behind the attack.
Medical device maker iRhythm disclosed a data breach affecting at least 360,000 people following a June cyberattack. The incident occurred on 8 June when hackers accessed third-party systems through social engineering, the company said in regulatory filings this week. The stolen information includes names, addresses, phone numbers, patient account numbers, device serial numbers, insurance numbers, dates of service, and birth dates. Hackers had access to company systems between 3 June and 8 June. iRhythm, known for its Zio Patch cardiac monitoring sensor, said the breach did not affect clinical systems, medical devices, or operations. The company reported receiving ransom demands but provided no evidence of identity theft. iRhythm reported $224.2 million in Q2 revenue.
iRhythm reported strong second-quarter results, beating analyst estimates with revenue of $224.2 million, up 20.1% year-on-year. The cardiac monitoring company posted adjusted earnings per share of $0.58, significantly exceeding the $0.04 estimate. Adjusted EBITDA reached $43.3 million, a 65.7% beat against expectations. Management attributed the performance to sustained demand for the Zio platform and effective commercial execution across multiple healthcare channels. During the earnings call, analysts questioned management about synergies from the VitalConnect acquisition and the sustainability of margin gains. CEO Quentin Blackford emphasised the need for a multi-product approach in the cardiac monitoring market. The company raised its full-year revenue guidance to $885 million from $880 million. Operating margin improved to -1.1% from -10% in the prior-year quarter.
iRhythm Technologies shares fell 1.9% to $125.41 after Truist Securities slashed its price target from $160 to $18, despite maintaining a Buy rating. The dramatic cut overshadowed the company's strong second-quarter results, which saw revenue of $224.2 million, up 20.1% year-over-year, and earnings per share of $0.58, significantly beating consensus estimates. Following the earnings beat, iRhythm raised its full-year revenue guidance to $885 million at the midpoint. The cardiac monitoring company has experienced volatile trading, with 19 moves greater than 5% over the past year. iRhythm is down 28.4% year-to-date and trading 33.7% below its 52-week high of $189.25.
iRhythm Technologies reported second-quarter revenue of $224.2 million, up 20.1% year-on-year and beating analyst estimates of $219.2 million. The medical technology company's non-GAAP profit of $0.58 per share significantly exceeded consensus forecasts. The company attributed the performance to sustained demand for its Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. Operating margin improved to -1.1% from -10% in the prior-year quarter, driven by manufacturing automation and workflow optimisation. iRhythm raised its full-year revenue guidance to $885 million from $880 million. The company plans to leverage its pending VitalConnect acquisition to expand into mobile cardiac telemetry and remote patient monitoring markets.